OTC · FSNUY
Healthcare · Medical - Care Facilities
$13.20
Down-$0.14 (-1.05%)
Updated Aug 31, 2026, 2:33 PM
SID Score
6.2/10
Composite research score
Smart Money
46/100
Neutral
Price performance
1M range · 0 trading sessions · Daily adjusted prices
FSNUY does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning FSNUY.
FSNUY research
Company profile and research snapshot.
FRESENIUS SE S/ADR
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 13, 2026 | METZLER EQUITIES | Buy | — |
| Jul 12, 2026 | JEFFERIES | Buy | — |
| Jul 12, 2026 | DAY BY DAY | Buy | — |
| Jun 29, 2026 | DAY BY DAY | Hold | — |
| Jun 7, 2026 | BAADER EUROPE / ALPHAVALUE | Buy | — |
No generated briefing is available yet.
Yahoo · Aug 5, 2026
Fresenius SE & Co KGaA (FSNUY) delivers robust first-half results, lifting core EPS growth outlook to 10%-15% as biopharma surges 38% and Helios maintains resilient margins.
SeekingAlpha · Aug 5, 2026
Fresenius SE & Co. KGaA (FSNUY) Q2 2026 Earnings Call August 5, 2026 7:30 AM EDTCompany ParticipantsNick Stone - Senior VP of Investor Relations &...
SeekingAlpha · Aug 5, 2026
2026-08-05. The following slide deck was published by Fresenius SE & Co.
Yahoo · Aug 3, 2026
BAD HOMBURG, Germany, August 03, 2026--Fresenius Kabi, an operating company of Fresenius, announced today that the U.S. Food and Drug Administration (FDA) has approved a rituximab biosimilar developed by Dr. Reddy's Laboratories (DRL), a biosimilar to Rituxan®* (rituximab).1
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning FSNUY.
